Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 10/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6963302 | 0.86 | KDM4E (0.53) | LMNAKDM4EMAPTSMN1; SMN2NPC1 | |
| SCHEMBL29352033 | 0.86 | KDM4E (0.53) | LMNAKDM4EMAPTSMN1; SMN2NPC1 | |
| SCHEMBL6284717 | 0.86 | KDM4E (0.57) | LMNAALDH1A1KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL6280318 | 0.85 | SMN1; SMN2 (0.55) | LMNAALDH1A1KDM4EALOX12MAPT | |
| SCHEMBL29356264 | 0.84 | GAA (0.63) | LMNAALDH1A1KDM4EALOX12MAPT | |
| SCHEMBL1520344 | 0.83 | SMN1; SMN2 (0.71) | LMNAALDH1A1KDM4EALOX12MAPT | |
| SCHEMBL6953591 | 0.83 | KDM4E (0.53) | LMNAALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL6957303 | 0.83 | KDM4E (0.50) | LMNAALDH1A1KDM4EALOX12MAPT | |
| SCHEMBL8683561 | 0.81 | KDM4E (0.67) | LMNAALDH1A1KDM4EALOX12MAPT | |
| SCHEMBL6954481 | 0.80 | KDM4E (0.44) | LMNAALDH1A1KDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240251654-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2024-07-25 | — | — | US | claimed |
| CN-118103340-A | Method for manufacturing medical injection device and medical injection device manufactured by same | 斯特瓦纳托集团有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-12622947-B2 | Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof | PEPTRON, INC. (KR) | 2026-05-12 | — | — | US | disclosed |
| EP-4005587-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING LEVODOPA-INDUCED DYSKINESIA OR FOR SUPPRESSING PROGRESSION THEREOF | PEPTRON INC (KR) | 2026-03-18 | — | — | EP | disclosed |
| US-20250333645-A1 | [2,2]PARACYCLOPHANE-BASED METAL (II) COMPLEXES, ELECTRONIC DEVICES, APPARATUS, AND USE THEREOF | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2025-10-30 | — | — | US | disclosed |
| EP-4640691-A1 | [2,2]PARACYCLOPHANE-BASED METAL (II) COMPLEXES, ELECTRONIC DEVICES, APPARATUS, AND USE THEREOF | Zhejiang Huaxian Photoelectricity Technology Co., Ltd (CN) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025202284-A1 | GLP-1R ANTAGONISTS FOR THE TREATMENT OF CANCER | FIORINA PAOLO (IT) | 2025-10-02 | — | — | WO | disclosed |
| EP-4623928-A1 | GLP-1R ANTAGONISTS FOR THE TREATMENT OF CANCER | Fiorina, Paolo (IT) | 2025-10-01 | — | — | EP | disclosed |
| US-20250295587-A1 | COMPLEX LIPID NANOPARTICLES ENCAPSULATING POLYPEPTIDES AND USES THEREOF | SAIL BIOMEDICINES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250134895-A1 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-SYNUCLEIN-MEDIATED NEURODEGENERATION | UNIVERSITY HEALTH NETWORK (CA) | 2025-05-01 | — | — | US | disclosed |
| US-20240408312-A1 | METHOD OF MANUFACTURING A MEDICAL INJECTION DEVICE AND MEDICAL INJECTION DEVICE THUS OBTAINED | STEVANTO GROUP S.P.A. (IT) | 2024-12-12 | — | — | US | disclosed |
| EP-4005587-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING LEVODOPA-INDUCED DYSKINESIA OR FOR SUPPRESSING PROGRESSION THEREOF | Peptron, Inc. (KR) | 2022-06-01 | — | — | EP | disclosed |
| US-20220152139-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-05-19 | — | — | US | disclosed |
| CN-114206374-A | Pharmaceutical composition for treating levodopa-induced dyskinesia or for inhibiting progression thereof | 佩特通公司 | 2022-03-18 | — | — | CN | disclosed |
| US-11230599-B2 | Tumor mutational load | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-01-25 | — | — | US | disclosed |
| EP-0540143-B1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| US-5714503-A | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 1998-02-03 | — | — | US | disclosed |
| US-5593993-A | VIRICIDES FOR HTLV TREATMENT OF AIDS | MEDIVIR AB (SE) | 1997-01-14 | — | — | US | disclosed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | disclosed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250134895-A1 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-SYNUCLEIN-MEDIATED NEURODEGENERATION | SNCA, SAMHD1, MAPT | LMNA 576/4885ALDH1A1 1312/4885KDM4E 4222/4885 |
| US-20240251654-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | LEF1, EFNA1, EML4 | LMNA 3318/4885ALDH1A1 131/4885KDM4E 2782/4885 |
| US-20250333645-A1 | [2,2]PARACYCLOPHANE-BASED METAL (II) COMPLEXES, ELECTRONIC DEVICES, APPARATUS, AND USE THEREOF | OCIAD2, CCND2, OCIAD1 | LMNA 3355/4885ALDH1A1 1615/4885KDM4E 4026/4885 |
| US-12622947-B2 | Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof | GLP1R, GIPR, NPY1R | LMNA 2227/4885ALDH1A1 3414/4885KDM4E 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.